Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labat AfricaJSE:LAB Price-to-Tangible-Book is 0.20 as of Aug. 18, 2026, which is 97% below its 10-year median of 6.91. The stock has 8 warning signs investors should review. Among 839 Drug Manufacturers companies, Labat Africa ranks better than 98.33% on this metric.
The historical rank and industry rank for Labat Africa's Price-to-Tangible-Book or its related term are showing as below:
JSE:LAB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2 Med: 6.91 Max: 16
Current: 0.2
During the past 13 years, Labat Africa's highest Price to Tangible Book Ratio was 16.00. The lowest was 0.20. And the median was 6.91.
JSE:LAB's Price-to-Tangible-Book is ranked better than 98.33% of 839
companies
in the Drug Manufacturers industry
Industry Median: 2.26
vs JSE:LAB: 0.20
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Labat Africa Price-to-Tangible-Book Related Terms
Labat Africa Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Labat Africa's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:LAB vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Labat Africa's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Labat Africa (JSE:LAB) has a Price-to-Tangible-Book of 0.20 as of Aug. 18, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Labat Africa and its competitors. This is 97% below median its historical median of 6.91. Over the past decade, Labat Africa's Price-to-Tangible-Book has ranged from 0.20 to 16.00. According to the industry distribution chart, Labat Africa ranks #14 out of 839 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Labat Africa's Price-to-Tangible-Book too high?
Labat Africa's current Price-to-Tangible-Book of 0.20 is 97% below median its 10-year median of 6.91. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 16.00. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.26. Labat Africa's value of 0.20 is 91.2% below this industry median. Based on the distribution chart, Labat Africa ranks #14 out of 839 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #14 out of 839 companies for Price-to-Tangible-Book. This places Labat Africa in the top 2% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 2.26. Labat Africa's value of 0.20 is 91.2% below this benchmark. Historically, Labat Africa's own Price-to-Tangible-Book has ranged from 0.20 to 16.00 over the past decade. While the company's 10-year median is 6.91 vs. the industry median of 2.26, Labat Africa has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.26, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current Price-to-Tangible-Book of 0.20 is 91.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current Price-to-Tangible-Book is 0.20, which is 97% below median its own 10-year median of 6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.22, compared to a current price of R0.03 — trading 86.4% below its estimated fair value. The current Price-to-Tangible-Book is 0.20, which is 97% below median its 10-year median of 6.91 and 91.2% below the Drug Manufacturers industry median of 2.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Price-to-Tangible-Book is 0.20 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 
